Ubs Group Ag Ovid Therapeutics Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 30,612 shares of OVID stock, worth $29,387. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,612

Previous 21,192 44.45%

Holding current value

$29,387

Previous $16,000 125.0%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$0.75 - $1.3 $7,065 - $12,246	9,420 Added 44.45%	30,612 $36,000
Q2 2024 Aug 13, 2024	SELL	$0.7 - $3.34 $36,561 - $174,448	-52,230 Reduced 71.14%	21,192 $16,000
Q1 2024 May 13, 2024	BUY	$2.72 - $4.04 $4,050 - $6,015	1,489 Added 2.07%	73,422 $223,000
Q4 2023 Feb 09, 2024	BUY	$2.98 - $3.78 $71,001 - $90,062	23,826 Added 49.53%	71,933 $231,000
Q3 2023 Nov 09, 2023	SELL	$3.23 - $3.97 $4,906 - $6,030	-1,519 Reduced 3.06%	48,107 $184,000
Q2 2023 Aug 11, 2023	BUY	$2.53 - $3.89 $79,839 - $122,756	31,557 Added 174.65%	49,626 $162,000
Q1 2023 May 12, 2023	BUY	$1.88 - $2.85 $2,398 - $3,636	1,276 Added 7.6%	18,069 $46,000
Q4 2022 Feb 08, 2023	SELL	$1.43 - $1.89 $3,386 - $4,475	-2,368 Reduced 12.36%	16,793 $31,000
Q3 2022 Nov 10, 2022	BUY	$1.84 - $2.26 $5,917 - $7,268	3,216 Added 20.17%	19,161 $36,000
Q2 2022 Aug 10, 2022	BUY	$1.69 - $3.31 $1,597 - $3,127	945 Added 6.3%	15,945 $34,000
Q1 2022 May 16, 2022	SELL	$2.65 - $3.49 $11,334 - $14,926	-4,277 Reduced 22.19%	15,000 $47,000
Q4 2021 Feb 14, 2022	BUY	$3.13 - $3.73 $13,387 - $15,953	4,277 Added 28.51%	19,277 $62,000
Q2 2021 Aug 13, 2021	SELL	$3.3 - $4.49 $16,622 - $22,616	-5,037 Reduced 25.14%	15,000 $59,000
Q1 2021 May 12, 2021	SELL	$2.42 - $4.47 $2.44 Million - $4.51 Million	-1,009,556 Reduced 98.05%	20,037 $81,000
Q4 2020 Feb 11, 2021	BUY	$2.28 - $6.84 $1.32 Million - $3.96 Million	579,322 Added 128.66%	1,029,593 $2.38 Million
Q3 2020 Nov 12, 2020	BUY	$5.39 - $8.24 $1.71 Million - $2.61 Million	317,281 Added 238.58%	450,271 $2.58 Million
Q2 2020 Jul 31, 2020	SELL	$2.67 - $7.91 $200,180 - $593,044	-74,974 Reduced 36.05%	132,990 $980,000
Q1 2020 May 01, 2020	BUY	$2.03 - $4.35 $414,091 - $887,339	203,986 Added 5127.85%	207,964 $620,000
Q4 2019 Feb 14, 2020	BUY	$2.08 - $5.06 $8,274 - $20,128	3,978 New	3,978 $17,000
Q3 2019 Nov 14, 2019	SELL	$1.76 - $3.51 $12,073 - $24,078	-6,860 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$1.59 - $2.14 $10,907 - $14,680	6,860 New	6,860 $13,000
Q1 2019 May 14, 2019	SELL	$1.77 - $3.56 $17,878 - $35,959	-10,101 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.42 - $6.6 $16,468 - $44,913	6,805 Added 206.46%	10,101 $24,000
Q3 2018 Nov 14, 2018	BUY	$5.6 - $11.0 $1,803 - $3,542	322 Added 10.83%	3,296 $19,000
Q2 2018 Aug 14, 2018	BUY	$6.16 - $10.14 $18,319 - $30,156	2,974 New	2,974 $23,000
Q1 2018 May 15, 2018	SELL	$6.53 - $9.82 $1,482 - $2,229	-227 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$6.12 - $12.31 $9,443 - $18,994	-1,543 Reduced 87.18%	227 $2,000
Q3 2017 Nov 14, 2017	BUY	$5.32 - $9.77 $9,416 - $17,292	1,770	1,770 $15,000

Others Institutions Holding OVID

# of Institutions

Shares Held

39M

Call Options Held

37.4K

Put Options Held

500

View Full List

About Ovid Therapeutics Inc.

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $67.6M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

More about OVID

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account